(Total Views: 552)
Posted On: 05/18/2021 2:14:10 PM
Post# of 148899
In addition to this post by Jax6002, there were posts by mtruong34 (#90728) and docj (# 90711) about Dr. Jay's interview. I hesitate to make it 4 about the same interview, but that is how strongly I feel that all the longs should listen. It is over 1 hour long and many don't have that much time, so I am going to give some references for those who can't spend an hour listening.
The interviewer is very knowledgeable and she is the one who reached out to Dr. Jay. I suggest you start listening at about 36:00. He mentioned multiple threats at 39:00 including shorts, the HIV trial problems, a new drug which the FDA does not understand, the FDA frowns on all the PRs CYDY issued, etc. He notes that the antiviral division is handling this; it should be the pulmonary inflammation division but the FDA does no have one.
Interesting discussion at 44:45 that politicians don't want to get outside their lanes. He did find one in May 2020 - The New York Health Commissioner. He called the FDA and they essentially told him to mind your own business.
I can't tell exactly when this was recorded, but I believe it was last week.
He says many times he knows the drug works. He discusses 2 doses vs. 4 doses at 15:15.
Here is the description at Savage minds.
https://savageminds.substack.com/p/jay-lalezari
Jay Lalezari, MD is a physician and the Director of Quest Clinical Research who recently penned “Hope for Critically Ill Covid-19 Patients Within Reach” wherein he describes the results of a randomised, double-blind study of a drug called leronlimab (Vyrologix or PRO 140) which demonstrates a 82% reduction in the rate of death at Day 14 for patients on a ventilator who received 2 weekly doses of leronlimab compared to a placebo. Stressing the urgency for the FDA to approve leronlimab under an Emergency Use Authorization (EUA), Lalezari examines the various obstacles to achieving this end—from the ways in which Small Pharma faces greater economic hurdles compared to Big Pharma to the effort by short-sellers to sink CytoDyn, the producer of leronlimab, to the politics that allow Big Pharma to overpower smaller pharmaceutical companies strategically and economically. To confirm the finding for the FDA, CytoDyn must perform another trial of leronlimab that will take months to complete meanwhile critically ill patients in the Philippines are receiving leronlimab as part of the therapeutic treatment for critically ill COVID-19 patients and in Brazil some patients are well on the road to receiving this life-saving drug in Phase 3 trials soon to be conducted in up to 45 clinical sites.
The interviewer is very knowledgeable and she is the one who reached out to Dr. Jay. I suggest you start listening at about 36:00. He mentioned multiple threats at 39:00 including shorts, the HIV trial problems, a new drug which the FDA does not understand, the FDA frowns on all the PRs CYDY issued, etc. He notes that the antiviral division is handling this; it should be the pulmonary inflammation division but the FDA does no have one.
Interesting discussion at 44:45 that politicians don't want to get outside their lanes. He did find one in May 2020 - The New York Health Commissioner. He called the FDA and they essentially told him to mind your own business.
I can't tell exactly when this was recorded, but I believe it was last week.
He says many times he knows the drug works. He discusses 2 doses vs. 4 doses at 15:15.
Here is the description at Savage minds.
https://savageminds.substack.com/p/jay-lalezari
Jay Lalezari, MD is a physician and the Director of Quest Clinical Research who recently penned “Hope for Critically Ill Covid-19 Patients Within Reach” wherein he describes the results of a randomised, double-blind study of a drug called leronlimab (Vyrologix or PRO 140) which demonstrates a 82% reduction in the rate of death at Day 14 for patients on a ventilator who received 2 weekly doses of leronlimab compared to a placebo. Stressing the urgency for the FDA to approve leronlimab under an Emergency Use Authorization (EUA), Lalezari examines the various obstacles to achieving this end—from the ways in which Small Pharma faces greater economic hurdles compared to Big Pharma to the effort by short-sellers to sink CytoDyn, the producer of leronlimab, to the politics that allow Big Pharma to overpower smaller pharmaceutical companies strategically and economically. To confirm the finding for the FDA, CytoDyn must perform another trial of leronlimab that will take months to complete meanwhile critically ill patients in the Philippines are receiving leronlimab as part of the therapeutic treatment for critically ill COVID-19 patients and in Brazil some patients are well on the road to receiving this life-saving drug in Phase 3 trials soon to be conducted in up to 45 clinical sites.
(11)
(0)Scroll down for more posts ▼
